BankPlus Trust Department Purchases Shares of 92 Stryker Co. (NYSE:SYK)

BankPlus Trust Department acquired a new position in shares of Stryker Co. (NYSE:SYK) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 92 shares of the medical technology company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Parnassus Investments LLC bought a new stake in Stryker in the 3rd quarter valued at $762,798,000. RTW Investments LP acquired a new stake in shares of Stryker during the third quarter worth $143,392,000. State Street Corp boosted its position in shares of Stryker by 2.2% in the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock valued at $5,279,788,000 after acquiring an additional 316,404 shares during the period. FMR LLC grew its stake in shares of Stryker by 3.0% in the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock valued at $2,639,725,000 after acquiring an additional 215,782 shares in the last quarter. Finally, Public Sector Pension Investment Board increased its position in Stryker by 1,552.7% during the third quarter. Public Sector Pension Investment Board now owns 207,889 shares of the medical technology company’s stock worth $75,102,000 after acquiring an additional 195,310 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 0.7 %

Shares of NYSE:SYK opened at $390.57 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a market capitalization of $149.03 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a fifty day moving average of $378.78 and a 200-day moving average of $370.22.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the firm earned $3.46 earnings per share. On average, equities analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on SYK. UBS Group boosted their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price target on shares of Stryker in a research note on Wednesday, January 29th. JPMorgan Chase & Co. raised their price objective on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. Finally, Truist Financial raised their price target on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.